World ADC San Diego 2026 has ended. This guide stays up as the record of who was there. See upcoming conferences

Universities, institutes and hospitals at World ADC San Diego 2026

Oct 12–15, 2026 San Diego, CA ~1.3k attendees Website

6 universities, institutes and hospitals are at World ADC San Diego 2026 — 6 presentations on the program. Most represented: Binghamton University (1 on the program), Hangzhou Institute of Medicine, Chinese Academy of Sciences (1 on the program), Queen's University Belfast (1 on the program). As of Oct 8, 2026.

All 165 organizations at World ADC San Diego 2026 →

Showing 1–6 of 6 organizations

Organization	World ADC San Diego 2026 Attendance
Binghamton University Binghamton, NY
binghamton.edu Academic & healthcare Public research university in the State University of New York system.	Workshop Thu Oct 15 9:00am Assessing the Development & Emerging Potential of Immune- Stimulating & Immune-Suppressing ADCs in Oncology & Beyond Post-conference workshop for Discovery Chemistry & Discovery Biology
Hangzhou Institute of Medicine, Chinese Academy of Sciences Hangzhou, China
him.cas.cn Academic & healthcare Chinese Academy of Sciences research institute for biomedical and drug discovery research.	Talk Mon Oct 12 11:00am Exploring “ADC + Antibody” as an Emerging Combination Strategy for Solid Tumor Therapies Pre-conference: 10th ADCs in Combination Day
Queen's University Belfast Belfast, UK
qub.ac.uk Academic & healthcare Public research university in Northern Ireland.	Chair Introduction to ADCs Day Pre-conference: Introduction to ADCs Day · with Bramhill Biologics Consulting
UCLA Health Los Angeles, CA
uclahealth.org Academic & healthcare Academic health system of the University of California, Los Angeles, including its cancer care and clinical research programs.	Talk Mon Oct 12 2:00pm Exploring the Physician Perspective & Approaches to Mitigate ADC Toxicity & Improve Clinical Safety Pre-conference: 7th Toxicity Day
University of Chicago Chicago, IL
	Talk Tue Oct 13 5:15pm Evaluating I-SPY2 Clinical Data & Toxicity Monitoring to Assess ADC Progression to Early-Stage Oncology Settings in TNBC & HER2+ Breast Cancer Plenary Clinical development
University of Michigan Ann Arbor, MI
	Talk Mon Oct 12 2:00pm Utilizing Immune System Interactions & Fc Effector Function Analysis to Rationally Select Optimum ADC Combination Partners Pre-conference: 10th ADCs in Combination Day